

Andrea Varrone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1572156/publications.pdf>

Version: 2024-02-01

70
papers

3,291
citations

172457
29
h-index

155660
55
g-index

74
all docs

74
docs citations

74
times ranked

4206
citing authors

#	ARTICLE	IF	CITATIONS
1	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]PBR28 and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	3.9	18
2	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 632-651.	6.4	82
3	Nondisplaceable Binding Is a Potential Confounding Factor in [¹¹ C]PBR28 Translocator Protein PET Studies. Journal of Nuclear Medicine, 2021, 62, 412-417.	5.0	10
4	Simplified quantification of [¹⁸ F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1291-1300.	4.3	8
5	Sex correction improves the accuracy of clinical dopamine transporter imaging. EJNMMI Research, 2021, 11, 82.	2.5	9
6	[¹¹ C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins. Journal of Medicinal Chemistry, 2021, 64, 12003-12021.	6.4	15
7	Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials. NeuroImage: Clinical, 2021, 32, 102807.	2.7	3
8	New approach in radiometabolite analysis of positron emission tomography (PET) radioligands; lead-shielded microextraction by packed sorbent as a tool for in vivo radiometabolite analysis of [11C]SMW139 in rat plasma. Talanta, 2020, 208, 120449.	5.5	5
9	COVID-19 and the brain: impact on nuclear medicine in neurology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2487-2492.	6.4	18
10	Dopamine transporter imaging in neurodegenerative movement disorders: PET vs. SPECT. Clinical and Translational Imaging, 2020, 8, 349-356.	2.1	10
11	Timing is everything: tau imaging across stages of Alzheimer's disease. Brain, 2020, 143, 2634-2636.	7.6	1
12	Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Research, 2020, 1749, 147131.	2.2	21
13	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1885-1912.	6.4	134
14	PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2429-2439.	6.4	4
15	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. Movement Disorders, 2020, 35, 606-615.	3.9	25
16	High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2407-2416.	6.4	12
17	Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease. EJNMMI Research, 2020, 10, 95.	2.5	13
18	Effects of age, BMI and sex on the glial cell marker TSPO – a multicentre [11C]PBR28 HRRT PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2329-2338.	6.4	70

#	ARTICLE	IF	CITATIONS
19	PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 367-375.	6.4	50
20	Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects. Journal of Nuclear Medicine, 2018, 59, 1275-1280.	5.0	12
21	Nigrostriatal dopamine transporter availability in early Parkinson's disease. Movement Disorders, 2018, 33, 592-599.	3.9	73
22	Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT: a clinical comparison. EJNMMI Research, 2018, 8, 100.	2.5	51
23	Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Chorea. Current Neurology and Neuroscience Reports, 2018, 18, 85.	4.2	13
24	The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging. EJNMMI Research, 2017, 7, 10.	2.5	16
25	The immune response of the human brain to abdominal surgery. Annals of Neurology, 2017, 81, 572-582.	5.3	87
26	In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects. Neuropharmacology, 2017, 117, 171-181.	4.1	22
27	Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D 2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect. NeuroImage, 2017, 152, 330-339.	4.2	24
28	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 183-195.	3.1	85
29	Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 228-242.	3.1	34
30	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 214-227.	3.1	67
31	[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Physics, 2017, 4, 8.	2.7	46
32	Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of selegiline. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 382-391.	6.4	21
33	Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex. Journal of Nuclear Medicine, 2017, 58, 617-622.	5.0	19
34	Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data. EJNMMI Research, 2017, 7, 58.	2.5	33
35	Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models. Neuron, 2016, 92, 1220-1237.	8.1	92
36	Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data. NeuroImage, 2016, 133, 313-320.	4.2	11

#	ARTICLE	IF	CITATIONS
37	Guidelines to PET measurements of the target occupancy in the brain for drug development. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2255-2262.	6.4	28
38	In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. Brain, Behavior, and Immunity, 2016, 54, 149-157.	4.1	48
39	Low serotonin _{1B} receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder. Psychiatry Research - Neuroimaging, 2016, 253, 36-42.	1.8	21
40	Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using ¹⁸ F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. Journal of Nuclear Medicine, 2016, 57, 1529-1534.	5.0	21
41	Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1323-1336.	6.4	35
42	Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1315-1322.	6.4	29
43	In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, ¹⁸ F-Labeled Deuterated Fluorodeprenyl. Journal of Nuclear Medicine, 2016, 57, 315-320.	5.0	69
44	Test-retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 173-183.	6.4	106
45	Imaging of neuroinflammation: TSPO and beyond. Clinical and Translational Imaging, 2015, 3, 389-390.	2.1	7
46	¹⁸ F-HT _{1B} receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients. Synapse, 2015, 69, 365-374.	1.2	19
47	Positron Emission Tomography studies with [11C]PBR28 in the Healthy Rodent Brain: Validating SUV as an Outcome Measure of Neuroinflammation. PLoS ONE, 2015, 10, e0125917.	2.5	11
48	Amphetamine Decreases ¹²⁵ I-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain. International Journal of Neuropsychopharmacology, 2015, 18, pyu081-pyu081.	2.1	13
49	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain, 2015, 138, 2687-2700.	7.6	168
50	Diurnal and seasonal variation of the brain serotonin system in healthy male subjects. NeuroImage, 2015, 112, 225-231.	4.2	56
51	Quantitative Analysis of ¹⁸ F-(¹ E)-N-(3-Iodoprop-2-Enyl)-2 ¹² -Carbofluoroethoxy-3 ¹² -(4 ² -Methyl-Phenyl) Nortropine Binding to the Dopamine Transporter in Parkinson Disease. Journal of Nuclear Medicine, 2015, 56, 714-720.	5.0	46
52	Molecular imaging of neuroinflammation in Alzheimer's disease. Clinical and Translational Imaging, 2015, 3, 437-447.	2.1	11
53	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 438-446.	6.4	64
54	Human Brain Imaging of Dopamine Transporters. , 2014, , 203-240.		7

#	ARTICLE	IF	CITATIONS
55	Distinct regional age effects on [¹¹ C]AZ10419369 binding to 5-HT _{1B} receptors in the human brain. <i>NeuroImage</i> , 2014, 103, 303-308.	4.2	21
56	Reduced 5-HT _{1B} receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2014, 223, 164-170.	1.8	61
57	Association of central serotonin transporter availability and body mass index in healthy Europeans. <i>European Neuropsychopharmacology</i> , 2014, 24, 1240-1247.	0.7	34
58	Positron emission tomography imaging of 5-hydroxytryptamine _{1B} receptors in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 867-875.	3.1	25
59	European multicentre database of healthy controls for [¹²³ I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 213-227.	6.4	198
60	In vivo imaging of the 18-kDa translocator protein (TSPO) with [¹⁸ F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 921-931.	6.4	71
61	Simplified quantification and whole-body distribution of [¹⁸ F]FE-PE2I in nonhuman primates: prediction for human studies. <i>Nuclear Medicine and Biology</i> , 2012, 39, 295-303.	0.6	15
62	New developments of dopaminergic imaging in Parkinson's disease. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, , .	0.7	0
63	New developments of dopaminergic imaging in Parkinson's disease. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 56, 68-82.	0.7	22
64	Kinetic Analysis and Quantification of the Dopamine Transporter in the Nonhuman Primate Brain with [¹¹ C]-PE2I and [¹⁸ F]-FE-PE2I. <i>Journal of Nuclear Medicine</i> , 2011, 52, 132-139.	5.0	51
65	Imaging of the Striatal and Extrastriatal Dopamine Transporter with [¹⁸ F]-LBT-999: Quantification, Biodistribution, and Radiation Dosimetry in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1313-1321.	5.0	19
66	Molecular Imaging of the Dopamine Transporter. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1331-1334.	5.0	82
67	Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1639-1650.	6.4	173
68	EANM procedure guidelines for PET brain imaging using [¹⁸ F]FDG, version 2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 2103-2110.	6.4	469
69	In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [¹⁸ F]FE-PE2I, a new dopamine transporter PET radioligand. <i>Synapse</i> , 2009, 63, 871-880.	1.2	56
70	Synthesis and PET evaluation of (R)-[S-methyl- ¹¹ C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 1007-1019.	1.0	14